Patients with liver metastases from squamous cell head and neck cancer (SCHNC) are usually treated with chemotherapy and are not evaluated for eventual liver-directed treatment. However, the potential benefits from liver surgery for the patients with hepatic-only metastases from SCHNC generally remain undefined. We report a patient with late liver-only metastases from squamous cell glottic cancer treated with resection of the liver metastases followed by adjuvant platinum-based chemotherapy plus cetuximab. The patient died 25 months after resection of the hepatic metastases from widespread hepatic and pulmonary recurrence. The literature data as well as this case demonstrates the capability of liver surgery to prolong survival in patients with hepatic metastases from SCHNC.
Neuroendocrine tumors arise from the diffuse neuroendocrine system and secrete several peptides and bioactive amines (serotonin, histamine, dopamine, norepinephrine, corticotropin, calcitonin, bradykinin, kalikrein, gastrin, cholecystokinin, prostaglandins). The most common occurrence site of neuroendocrine tumors is the ileum. The symptoms of small bowel carcinoids are represented by intermittent intestinal obstruction and carcinoid syndrome. Presence of the carcinoid syndrome usually indicates hepatic or retroperitoneal metastases. The typical carcinoid syndrome is characterized by flushing, diarrhea, nonspecific abdominal pain and bronchospasm. The diagnosis of small bowel tumors is often difficult due to their rarity and the nonspecific and variable nature of the presenting signs and symptoms. The most useful initial diagnostic test for the carcinoid syndrome is to measure 24-hour urinary excretion of 5-hydroxyindolacetic acid (5 HIAA), which is the end product of serotonin metabolism. Capsule endoscopy is a more recent diagnostic tool. Surgery is the radical form of curative therapy for carcinoid tumors. Numerous therapies are available for palliation including surgery, pharmacologic therapy, interventional radiologic therapy, embolization and chemoembolization of hepatic metastases, immunotherapy (Interferon alfa) and chemotherapy. We carefully reviewed the available literature on this topic before beginning our study.
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.